JP2012515164A5 - - Google Patents

Download PDF

Info

Publication number
JP2012515164A5
JP2012515164A5 JP2011545490A JP2011545490A JP2012515164A5 JP 2012515164 A5 JP2012515164 A5 JP 2012515164A5 JP 2011545490 A JP2011545490 A JP 2011545490A JP 2011545490 A JP2011545490 A JP 2011545490A JP 2012515164 A5 JP2012515164 A5 JP 2012515164A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
corneal
subject
nerve
inhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011545490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515164A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/020646 external-priority patent/WO2010081091A2/en
Publication of JP2012515164A publication Critical patent/JP2012515164A/ja
Publication of JP2012515164A5 publication Critical patent/JP2012515164A5/ja
Pending legal-status Critical Current

Links

JP2011545490A 2009-01-09 2010-01-11 角膜障害を処置するための治療組成物 Pending JP2012515164A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14356109P 2009-01-09 2009-01-09
US61/143,561 2009-01-09
PCT/US2010/020646 WO2010081091A2 (en) 2009-01-09 2010-01-11 Therapeutic compositions for treatment of corneal disorders

Publications (2)

Publication Number Publication Date
JP2012515164A JP2012515164A (ja) 2012-07-05
JP2012515164A5 true JP2012515164A5 (cg-RX-API-DMAC7.html) 2013-07-25

Family

ID=42144303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011545490A Pending JP2012515164A (ja) 2009-01-09 2010-01-11 角膜障害を処置するための治療組成物

Country Status (6)

Country Link
US (1) US10117906B2 (cg-RX-API-DMAC7.html)
EP (1) EP2385839B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012515164A (cg-RX-API-DMAC7.html)
AU (1) AU2010203425B2 (cg-RX-API-DMAC7.html)
CA (1) CA2749537C (cg-RX-API-DMAC7.html)
WO (1) WO2010081091A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230776T1 (hr) * 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Himerni antagonisti receptora il-1 tipa i
WO2012103240A2 (en) * 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
WO2013126599A1 (en) 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Meibomian gland dysfunction
WO2013126602A1 (en) 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
WO2014036445A2 (en) * 2012-08-31 2014-03-06 Johnson Michael R Novel mucolytic agents
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ, インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
SG11201601291QA (en) 2013-08-23 2016-03-30 Parion Sciences Inc Dithiol mucolytic agents
JP6377618B2 (ja) * 2013-08-28 2018-08-22 千寿製薬株式会社 角膜上皮障害治療剤
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
BR112017016067A2 (pt) 2015-01-30 2018-04-03 Parion Sciences Inc agentes mucolíticos de monotiol
JP2018520986A (ja) 2015-04-30 2018-08-02 パリオン・サイエンシィズ・インコーポレーテッド ジチオール粘液溶解剤の新規なプロドラッグ
US20180312838A1 (en) * 2015-10-21 2018-11-01 The Regents Of The University Of California Modulation of microrna 184 to treat pathological lymphangiogenesis
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
WO2020218488A1 (ja) * 2019-04-26 2020-10-29 千寿製薬株式会社 眼疾患マーカー
CN113350326B (zh) * 2021-07-28 2023-03-17 爱尔眼科医院集团股份有限公司 化合物lm22b-10在制备角膜上皮及神经损伤治疗药物中的应用
KR102883890B1 (ko) * 2021-11-30 2025-11-07 한림대학교 산학협력단 miR-30c-1 발현 수준을 증가시키기 위한 제제를 사용하는 각막 내피 세포 배양 방법 및 각막 내피 세포 질환 치료용 조성물
CN118304388B (zh) * 2024-04-03 2025-02-11 南通大学 Tak1在制备治疗周围神经损伤药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610336B1 (en) 1991-10-31 2002-03-27 The Victoria University Of Manchester Treatment of neurological conditions by an interleukin-1 inhibiting compound
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
WO1998022130A1 (en) * 1996-11-19 1998-05-28 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
JP3363832B2 (ja) 1999-05-13 2003-01-08 アルプス電気株式会社 薄膜構造体およびその製造方法
US20030104041A1 (en) 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
EP1252895A4 (en) 2000-01-31 2003-04-16 Santen Pharmaceutical Co Ltd REMEDIES FOR OPHTHALMIC DISORDERS
WO2001057082A2 (en) 2000-02-03 2001-08-09 Regeneration Technologies, Inc. Extraction of growth factors from tissue
US20010047204A1 (en) * 2000-03-20 2001-11-29 Medennium, Inc. Method for determination of a properly sized posterior chamber phakic refractive lens
US20020131954A1 (en) 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20050143333A1 (en) 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
WO2003022213A2 (en) 2001-09-06 2003-03-20 Board Of Regents, The University Of Texas System Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor
US7683165B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US6890654B2 (en) 2002-04-18 2005-05-10 Northwestern University Encapsulation of nanotubes via self-assembled nanostructures
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20050033694A1 (en) * 2003-06-03 2005-02-10 United States Postal Service. System and method for fleet card management
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US20050023872A1 (en) * 2003-07-28 2005-02-03 Hetzel Thomas R. Modular seat cushion with interlocking human support and base portions and method of creating and using a seat cushion
KR100543466B1 (ko) * 2003-11-13 2006-01-20 삼성전자주식회사 영상 보간 장치 및 방법
GB0404693D0 (en) 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
JP4815808B2 (ja) 2005-01-24 2011-11-16 三菱電機株式会社 ロータリ圧縮機
CN102293774A (zh) 2005-03-31 2011-12-28 旭硝子株式会社 前列腺素F2α衍生物的应用
EP1870099A4 (en) 2005-04-13 2008-07-16 Ube Industries PROTECTION AGAINST RETINAL NERVOUS CELLS WITH INDAZOLE DERIVATIVE AS ACTIVE SUBSTANCE
US7670849B2 (en) 2005-04-29 2010-03-02 Henkin Robert I Method for diagnosing insulin resistance from nasal secretions
DE602006009834D1 (de) * 2005-09-01 2009-11-26 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
KR20110079922A (ko) * 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 il-1 항체의 용도
US20080026485A1 (en) * 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
CN101489569A (zh) 2006-06-12 2009-07-22 席拉坎有限责任公司 眼表面疾病的局部治疗
CA2679588A1 (en) * 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
US8399421B2 (en) 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
EP2187900B1 (en) 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CA2711696C (en) * 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
US9011861B2 (en) * 2010-02-25 2015-04-21 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease

Similar Documents

Publication Publication Date Title
JP7358221B2 (ja) 老視を治療するための組成物及び方法
Awwad et al. Principles of pharmacology in the eye
JP5886523B2 (ja) 眼の炎症性障害を処置するための治療組成物
JP2022502421A5 (cg-RX-API-DMAC7.html)
JP2011517659A5 (cg-RX-API-DMAC7.html)
AU2010203425B2 (en) Therapeutic compositions for treatment of corneal disorders
KR20180014824A (ko) 눈의 굴절 이상 치료 방법 및 저장 안정성 조성물
JP7324208B2 (ja) 近視進行の治療
US20210299219A1 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
EP2525793A2 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
JP6267003B2 (ja) ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
KR20200116953A (ko) 안내 혈관 신생 및/또는 안내 혈관 투과성 항진을 수반하는 안과 질환의 예방 또는 치료를 위한 의약
US20120014970A1 (en) Therapeutic Compositions for Treatment of Corneal Disorders
CA2819616A1 (en) Methods for treating diseases of the retina
JP2009519232A5 (cg-RX-API-DMAC7.html)
WO2017043612A1 (ja) ドライアイ改善剤
ITMI20110583A1 (it) Preparazioni oftalmiche a base di pacap (pituitary adenylate cyclase activating polypeptide) al fine di ripristinare la normale funzione visiva nel glaucoma in fase precoce
WO2022259211A1 (en) Ophthalmic compositions and/or methods for presbyopia, mydriasis and/or ocular discomfort management
JP2005306815A (ja) 眼障害を予防および/または治療するための眼科用組成物
JP2019151628A (ja) 角膜上皮障害治療剤
Lim Recent Developments in Glaucoma
Mohamadi et al. The effect of phacoemulsification with posterior chamber intraocular lens implantation on intraocular pressure and anterior chamber depth